Medgenics (MDGN) Narrows Q3 Loss

Medgenics (NYSE: MDGN) reported Q3 EPS of ($0.21), versus ($0.33) reported last year.

For earnings history and earnings-related data on Medgenics (MDGN) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
• Bernstein SocGen on Performance Food Group (PFGC): 'Not the quarter we were hoping for, but LT story intact'